)

Traws Pharma (TRAW) investor relations material
Traws Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Advanced clinical programs for COVID-19 and influenza antivirals, with reprioritized plans to maximize near-term value and ongoing discussions for pandemic stockpiling.
Phase 2 studies for Ritutrelvir targeting COVID-19, including Paxlovid-ineligible patients, expected to report results by year-end 2025.
Deferred initiation of bird flu clinical trial due to low incidence, with regulatory approvals in Australia and South Korea for rapid start if needed.
Published strong efficacy data for rigosertib in rare oncology indication, seeking partnership for further development.
Management changes included new interim CEO, CFO, and Chairman appointments during Q2 2025.
Financial highlights
Q2 2025 revenue was $2.7M, up from $57K in Q2 2024, due to recognition of deferred revenue from a terminated licensing agreement.
Net loss for Q2 2025 was $0.9M ($0.11 per share), compared to a net loss of $123.1M ($20.52 per share) in Q2 2024, which included a $117.5M non-cash charge.
Cash, cash equivalents, and short-term investments totaled $13.1M as of 06/30/2025, down from $21.3M at 12/31/2024.
R&D expenses decreased to $2.3M from $4.0M year-over-year, mainly due to lower oncology and personnel costs.
G&A expenses fell to $1.7M from $2.0M, reflecting lower personnel and stock-based compensation.
Outlook and guidance
Results from Phase 2 Ritutrelvir studies anticipated by year-end 2025.
Focused on advancing Tevoxavir Marboxil for pandemic stockpiling, with trial initiation dependent on bird flu incidence.
Committed to partnering legacy oncology assets for further development and commercialization.
Expects significant expenses and operating losses to continue; additional financing required for ongoing trials and operations.
R&D expenditures in 2025 expected to be higher than 2024 due to virology program investments.
Next Traws Pharma earnings date

Next Traws Pharma earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage